Johnson & Johnson $JNJ Shares Sold by Shariaportfolio Inc.

Key Points

• Shariaportfolio Inc. reduced its stake in Johnson & Johnson by 13.9%, now holding 11,908 shares worth $1.82 million, making it the firm's 15th largest position.
• Johnson & Johnson reported $2.77 EPS for the quarter, exceeding estimates, with revenue of $23.74 billion, up 5.8% year-over-year.
• The company announced a quarterly dividend of $1.30, with an annualized yield of 2.7% and a payout ratio of 55.61%.

Shariaportfolio Inc. decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,908 shares of the company's stock after selling 1,920 shares during the quarter. Johnson & Johnson comprises about 0.8% of Shariaportfolio Inc.'s holdings, making the stock its 15th largest position. Shariaportfolio Inc.'s holdings in Johnson & Johnson were worth $1,819,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $190.97 on Friday. The business's 50 day moving average is $178.01 and its two-hundred day moving average is $163.56. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $192.10. The firm has a market cap of $459.92 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 2.42 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the company posted $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Analyst Ratings Changes

A number of research firms recently issued reports on JNJ. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a "buy" rating in a research report on Thursday. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, HSBC increased their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $191.41.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.